Takeda Pharmaceutical Company (TAK) is up 5% premarket on light volume. Shares have rallied 23% since mid-December. Earlier this week, it completed its acq
The combined company of Takeda and Shire will a global leader in the biopharmaceutical industry with complementary positions in gastroenterology (GI) and neuros
The rapidly changing pharmaceutical landscape reached another milestone today as Takeda (NYSE:TAK) became a top 10 global drugmaker by completing its $62B acquisition of Shire...
Investors in Shire plc (NASDAQ:SHPG) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 7, 2018 $150.00 Put had some of...
Shire plc (NASDAQ:SHPG) announced that the European Commission (EC) has granted marketing approval to Takhzyro (lanadelumab) subcutaneous injection, for routine prevention of...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||BUY||Strong Buy||Strong Buy||Strong Buy|
|Summary||Strong Buy||Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||1W||1||Dec 30, 2018|
|Bullish doji Star||30||1||Jan 04, 2019 03:00PM|
|Bullish Engulfing||1W||2||Dec 23, 2018|
|Petroleo Brasileiro Petrobras ADR||16.63||16.75||16.53||-0.02||-0.12%||11.55M||22/02|
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience Ophthalmology, Hematology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.